

1 Title:

2 **Fetal *Ureaplasma parvum* bacteraemia as a function of gestation-dependent complement**  
3 **insufficiency: evidence from a sheep model of pregnancy.**

4 Authors:

5 **Matthew W. Kemp,<sup>\*1</sup> Shatha Ahmed,<sup>†§</sup> Michael L. Beeton,<sup>¶</sup> Matthew S. Payne<sup>\*</sup>, Masatoshi**  
6 **Saito,<sup>\*1</sup> Yuichiro Miura,<sup>\*1</sup> Haruo Usuda,<sup>\*1</sup> Suhas G. Kallapur,<sup>\*#</sup> Boris W. Kramer,<sup>\*\*\*</sup> Sarah**  
7 **J. Stock,<sup>\*\*†</sup> Alan H. Jobe,<sup>\*#</sup> John P. Newnham,<sup>\*</sup> and Owen B. Spiller<sup>\*†</sup>**

8 Institutions:

9 **\*. School of Women's and Infants' Health, The University of Western Australia, Perth, Australia.**

10 **†. Cardiff University, School of Medicine, All Wales Antibiotic Resistance Engagement (AWARE)**  
11 **unit, University Hospital of Wales, Cardiff, CF14 4XN, UK.**

12 **§. Department of Pathology, Nineveh College of Medicine, University of Mosul, Mosul, Iraq.**

13 **¶. Cardiff Metropolitan University, Cardiff School of Health Sciences, Cardiff, CF5 2YB, UK**

14 **||. Tohoku University Hospital, Sendai, Miyagi Prefecture, Japan.**

15 **#. Cincinnati Children's Hospital Medical Center, Cincinnati, University of Cincinnati, OH**  
16 **45229, USA.**

17 **\*\*.** Department of Paediatrics, Maastricht University Medical Center, P. Debyelaan 25, 6202 AZ,  
18 **Maastricht, The Netherlands.**

19 **††.** MRC Centre for Reproductive Health, University of Edinburgh, Queen's Medical Research  
20 **Institute, UK.**

21

22 Running title: **Bacteraemia and Complement Insufficiency.**

23 Corresponding Author: **Dr. Owen B. Spiller, School of Medicine, Cardiff University, 5<sup>th</sup>**  
24 **floor University Hospital, Heath Park, Cardiff, CF14 4XN, United Kingdom.**

25 Phone: +44 (0)2920 742394 Fax: +44 (0)2920 744283 E-mail: **SpillerB@cardiff.ac.uk**

26

27

28

29 **Abstract.**

30 **Problem** Complement is a central defence against sepsis and increasing complement  
31 insufficiency in neonates of greater prematurity may predispose to increased sepsis.

32 *Ureaplasma* spp. are the most frequently cultured bacteria from preterm blood samples.

33 **Method of Study** A sheep model of intrauterine *Ureaplasma parvum* infection was used to  
34 examine *in vivo* *Ureaplasma* bacteraemia at early and late gestational ages. Complement  
35 function and *Ureaplasma* killing assays were used to determine the correlation between  
36 complement potency and bactericidal activity of sera *ex vivo*.

37 **Results** *Ureaplasma* were cultured from 50% of 95-day gestation lamb cord blood samples  
38 compared to 10% of 125-day gestation lambs. Bactericidal activity increased with increased  
39 gestational age and a direct correlation between functional complement activity and bactericidal  
40 activity ( $R^2=0.86$ ;  $p<0.001$ ) was found for 95-day gestational lambs.

41 **Conclusions** *Ureaplasma* bacteraemia *in vivo* was confined to early preterm lambs with low  
42 complement function, but *Ureaplasma* infection itself didn't diminish complement levels.

43

44 **INTRODUCTION**

45 The complement system encompasses a series of >30 serum proteins that interact through an  
46 amplification cascade following activation by foreign microbial surfaces, immune complexes,  
47 surface-bound antibodies or pathogen-bound pattern recognition molecules. Like most  
48 elements of the innate immune system, the complement system does not require previous  
49 exposure to be effective. Complement also acts to integrate the innate and humoral immune  
50 responses through recruiting innate and adaptive immune cells to the site of activation (via  
51 chemotaxin and anaphylotoxin release), improving the humoral response through a natural  
52 adjuvant activity, and increasing engulfment of microbes through decorating the surface with  
53 opsonins.<sup>1</sup> Complement has direct anti-microbial activity mediated by the formation of lytic  
54 pores on activating surfaces, which makes it a pivotal barrier to initial invasion by pathogens.  
55 However, as we have previously reviewed, the complement system does not have full potency  
56 (for both activation and regulatory factors) at birth in humans due to lower circulating levels of  
57 some of the components and this insufficiency is greater with increasing prematurity.<sup>2</sup> The  
58 reduced capacity of the complement system at term and birth, which is exacerbated with  
59 increasing prematurity, has been proposed to be responsible for the increased susceptibility of  
60 neonates to bacterial infection and sepsis.<sup>3</sup>

61

62 Intrauterine infection by *Ureaplasma parvum* (UP) is strongly associated with preterm birth,  
63 and is among the organisms most commonly isolated from gestational tissues.<sup>4,5</sup> UP is one of  
64 the smallest self-replicating microorganisms identified to date with a minimal genome (0.75-  
65 0.78 Mbp) that limits it to a parasitic existence.<sup>6</sup> Most notably, the UP genome does not encode  
66 any components that make up a cell wall, which is common to most bacteria and therefore  
67 inherently resistant to all classes of antibiotics that function by inhibiting cell wall synthesis.  
68 The cell wall also confers a protective effect against membrane attack complex-mediated

69 complement killing (particularly effective for Gram-positive bacteria), which may explain why  
70 UP is relatively susceptible to human complement.<sup>7</sup>

71

72 Ureaplasma bacteraemia is detected in up to 23% of preterm cord blood samples<sup>4</sup> and was  
73 isolated from blood samples in a cohort of 200 preterm neonates<sup>8</sup>, showing that this organism  
74 represents one of the most prevalent systemic infections in births under 32 weeks gestational  
75 age. To determine if sheep could be used as an *in vivo* model to investigate the correlation of  
76 complement development and bacteraemia with increasing prematurity observed in humans,  
77 we have examined bacteraemia and complement function using a well-established experimental  
78 model for *in utero* UP infection.<sup>9-11</sup> Here we investigate the ability of adult and preterm sheep  
79 sera to kill *U. parvum in vitro*, and investigate the presence of fetal *U. parvum* bacteraemia  
80 following experimental intrauterine infection *in vivo*. We hypothesised that, in a sheep model  
81 of pregnancy, the degree of gestation-dependent complement insufficiency in preterm lambs  
82 would correlate with fetal UP bacteraemia. To investigate this hypothesis, we examined: **i**)  
83 plasma titres of UP from lambs delivered at early- (95 d) and mid- (125 d) term gestations; **ii**)  
84 fetal anti-UP antibody responses; **iii**) UP killing activity of serum from adult sheep and preterm  
85 lambs; and **iv**) the kinetics and calcium dependence of serum UP killing activity.

86

## 87 **METHODS**

### 88 *Animal Studies*

89 All experimental sheep procedures were performed in Perth, Australia following approval by  
90 the University of Western Australia Animal Ethics Committee (RA/3/100/1289). 37 date-mated  
91 merino-cross ewes (*Ovis aries*) carrying singleton pregnancies were separated into 5 groups.  
92 Two groups received a received a single intraamniotic (IA) injection of sterile saline (**Group 1**;  
93 controls; n=5) or 10<sup>5</sup> infectious units of UP at 80 d GA (**Group 2**; n=8), for delivery at 95 d  
94 GA. Three further groups received a single IA injection of sterile saline (**Group 3**; controls;

95 n=6) or  $10^5$  infectious units of UP at 70 (**Group 4**; n=8) or 115 d GA (**Group 5**; n=10) for  
96 delivery at 125 d GA. Injections were carried out under ultrasound guidance as described  
97 previously.<sup>12</sup> Maternal blood was collected into serum separator and EDTA plasma tubes by  
98 peripheral venepuncture prior to euthanasia with intravenous pentobarbitone (100mg/kg) at  
99 either 95 (Groups 1 and 2), or 125 d GA (Groups 3, 4 and 5). The fetus was surgically delivered  
100 under terminal anaesthesia. Fetal viability at time of euthanasia was confirmed by ultrasound  
101 cardiac imaging and by fetal arterial cord blood gas analysis (Table 1). Fetal amniotic fluid and  
102 arterial cord blood (both serum and plasma) were obtained during surgical delivery by aseptic  
103 technique to ensure no cross contamination. Samples for serum (and plasma) separation were  
104 immediately dispensed into serum separator tubes (Becton-Dickinson) and placed on ice.  
105 Serum was separated by centrifugation at 2500 xg for 20 minutes prior to immediate aliquoting  
106 into sterile tubes and transfer to -80°C until analysis. Serum and plasma samples were processed  
107 in under 3 hours after collection (kept on ice at all intervals) until separation and freezing at -  
108 80°C. UP levels in plasma and amniotic fluid were determined by culture in triplicate  
109 immediately upon delivery (on fresh samples, not frozen and thawed), as detailed below.  
110 Maternal blood samples for comparative complement function assays were collected from  
111 pregnant, UP-naïve ewes into serum separator tubes as above.

112

### 113 *Ureaplasma parvum* culture and killing assay.

114 The serovar 3 strain HPA5 of *Ureaplasma parvum* (UP)<sup>13</sup> was used for all experiments. UP  
115 was cultured using commercial *Ureaplasma* selective medium (USM; Mycoplasma experience  
116 Ltd., Surrey, UK), using standard techniques as previously outlined.<sup>14</sup> UP titres were quantified  
117 by serial 10-fold dilution (or 2-fold dilution for killing assay) in USM, in triplicate and  
118 incubated at 37°C for 48 h prior to recording results. Killing assays were performed as for  
119 previous human serum studies,<sup>14</sup> with the exception of experiments to determine the rate of

120 serum killing. For those experiments, 10mM EDTA (final concentration) was added to block  
121 further complement activation at defined incubation times and the serum removed by  
122 centrifugation and resuspension in USM prior to titration of surviving bacteria. Transient  
123 exposure to EDTA was not found to alter growth of UP in separate experiments. Serum killing  
124 was calculated as the fold decrease relative to the titration of surviving bacteria following  
125 identical exposure to the same sera, except that all complement activity had been removed by  
126 heat-inactivation at 56°C for 30 minutes prior to the experiment.

127

### 128 ***Haemolysis assay***

129 Haemolysis assays were performed as previously published.<sup>15</sup> Guinea pig erythrocytes were  
130 purchased from TCS Biosciences (Oxford, UK) and sensitised with rabbit polyclonal anti-  
131 guinea pig erythrocyte antibodies purchased from Fitzgerald Industries International (North  
132 Acton, MA), as described previously.<sup>15</sup> Sheep serum from pregnant ewes and their singleton  
133 lambs were obtained by peripheral venepuncture of Merino- cross ewes and fetal cord blood  
134 was obtained from their lambs during surgical delivery at 95 and 125 d GA. Sera from both  
135 uninfected control and UP infected sheep were examined. Sera were stored at -80°C prior to  
136 use and aliquots only thawed once.

137

### 138 ***IgG quantitation and anti-UP response***

139 IgG concentrations in all sera were determined by commercial Sheep IgG ELISA (Life  
140 Diagnostics Inc., West Chester, PA) as per manufacturer's instructions. Results were performed  
141 in duplicate and assays were repeated once. IgG is not transferred across the ovine placenta<sup>16,17</sup>  
142 resulting in hypogammaglobulinemia in presuckle lambs;<sup>18</sup> therefore, *in utero* IgG levels can  
143 only have arisen by production by the fetus. The reactivity of fetal antibodies for UP in the fetal  
144 sera was determined by immunoblot analysis as previously described for human studies.<sup>14</sup> Total

145 protein equivalent to 30 µg of HPA5 per lane was separated by non-reducing polyacrylamide  
146 electrophoresis prior to electrophoretic transfer to nitrocellulose membranes. A non-related UP  
147 serovar 6 strain (HPA61) was also included to examine the presence of pan-UP reacting  
148 antibodies. Primary antibodies consisted of fetal or maternal sera at a final dilution of 1/100,  
149 subsequently detected with peroxidase-conjugated donkey anti-sheep antibodies (minimum  
150 species cross-reaction, Jackson ImmunoResearch UK).

151

### 152 *Statistical analyses.*

153 All values represent mean ± standard deviation (SD). Statistical analyses were performed using  
154 IBM SPSS Statistics for Windows, Version 20.0 (IBM Corporation, Armonk, NY.). Data were  
155 assessed for normality using Shapiro-Wilk tests. Normally distributed data, were tested either  
156 for significant mean differences by one-way ANOVA (for one factor) or where indicated by two  
157 factor ANOVA (e.g. age of serum source versus serum dilution), employing a critical value of  
158 0.05. Post-hoc analysis was performed with Bonferroni's post-hoc test comparing only relevant  
159 groups to control. Between groups differences in non-parametric data were tested for  
160 significance with Kruskal-Wallis one-way ANOVA employing a critical value of 0.05. Multiple  
161 post-hoc comparisons for non-parametric data were performed using Rank-Sum tests with a  
162 critical value corrected for  $n$  multiple comparisons. Slope of the growth curve to analyse  
163 amniotic fluid titres for UP during experimental infection establishment, as well as Y-intercept  
164 and goodness of fit statistics, were performed by GraphPad Prism (La Jolla, CA) using non-  
165 linear regression for exponential growth. Correlation between the lysis of guinea pig  
166 erythrocytes and UP killing for each serum sample was performed as untransformed data  
167 (Pearson  $r=0.55$ ;  $R^2=0.30$ ,  $p<0.05$ ), however, the relationship between UP killing and sera  
168 concentration was found to be logarithmic, therefore, correlation between  $\log_{10}$  killing and

169 serum lysis was much clearer and analysis on transformed data was more significant (Pearson  
170  $r=0.93$ ,  $R^2=0.86$ ;  $p<0.001$ )

171

172



173 **RESULTS**174 *Ureaplasma-cidal activity of serum from adult sheep and preterm lambs.*

175 The capacity for sera collected from UP-naïve adult and preterm lambs from Group 1 (95 d GA)  
176 and Group 3 (125 d GA) were examined for its ability to kill the parental UP strain (HPA5) used  
177 for experimental intrauterine infection in the present study (Figure 1A). Sera from uninfected  
178 adult sheep and preterm lambs was used to assess the innate immune killing and sera were  
179 confirmed to be devoid of anti-UP cross-reacting antibodies when tested by immunoblot (data  
180 not shown). Adult sera at dilutions as low as 6.25% (v/v) was capable of killing all added UP.  
181 Sera from control 125 d GA lambs (Group 3) had reduced capacity to kill *Ureaplasma*, requiring  
182 8-fold more sera (50% (v/v) dilution) to achieve bactericidal activity observed for adult sheep  
183 (Figure 1A), whereas 50% (v/v) sera from control 95 d GA lambs (Group 1) had 100-fold lower  
184 bactericidal activity than 125 d GA lamb sera. The kinetics of bactericidal activity in 50% (v/v)  
185 dilutions of sera were investigated by stopping complement function with EDTA at various time  
186 points for 95 d GA lamb sera and adult sheep sera (Figure 1B). Despite the reduced bactericidal  
187 activity, preterm and adult sera showed identical killing kinetics, achieving most of the killing in  
188 10-15 minutes of incubation at 37°C (Figure 1B) and 95 d GA sera did not show any increase in  
189 bactericidal activity even if incubation was extended to 4 h (data not shown). Bactericidal  
190 activity was found to be calcium dependent for both preterm and adult sera, as dilution in 10mM  
191 EGTA with additional Mg<sup>2+</sup> showed no killing when complement activity was restricted to the  
192 alternative activation pathway (Figure 1B).

193

194 *Plasma titres of UP from UP-infected lambs of different gestational ages.*

195 In agreement with the *in vitro* bactericidal assays, the ability to culture UP from the cord blood  
196 of experimentally infected 95 d GA lambs was significantly greater than from 125 d GA lambs  
197 (Figure 2). Lambs were surgically delivered at either: **Group 2)** 95 ± 2 d (25 d UP infection;

198 n=8); **Group 4**) 125 ± 2 d (42 d UP infection; n=8); or **Group 5**) 125 ± 2 d (10 d UP infection;  
199 n=10). Two fetuses in Group 2 died prior to delivery and were excluded from the study.  
200 Amniotic fluid UP titres were independent of the length of infection or gestational age (range =  
201  $5 \times 10^6$  -  $3 \times 10^7$  infectious units/mL; data not shown). However, the identification of fetal UP  
202 bacteraemia varied greatly between groups. None of the Group 4 animals had detectable UP  
203 bacteraemia; serum UP was detected in only one Group 5 fetus (500 infectious units/mL). In  
204 contrast, 50% of Group 2 lambs (delivered at 95 d GA) had UP bacteraemia ranging from 500-  
205 500,000 infectious units/mL (Table 1; Figure 2). None of the uninfected control animals (Groups  
206 1 and 3) had UP in either AF or fetal serum.

207

#### 208 *Immunoblot analysis of antibody response in preterm lambs.*

209 Measurement of total serum IgG showed minimal antibody levels in all Groups, apart from  
210 Group 4, which were exposed to intraamniotic UP for 42 days prior to delivery at 125 d GA  
211 (Figure 3A). Immunoblot analysis was performed on all sera, but only those with elevated IgG  
212 levels in group 4 were found to have anti-UP antibody response against the parental infecting  
213 strain (HPA5). Development of antibodies reacting to conserved antigens expressed by other  
214 non-infected strains was also evaluated by reactivity to an unrelated UP serovar 6 strain by  
215 immunoblot (Figure 3B). Despite elevated IgG levels in one of the Group 2 and one Group 5  
216 animal, these sera did not react with UP by immunoblot (Figure 3B). However, 66% of Group  
217 4 lambs (delivered at 125 d GA following 42 days UP infection) showed variable banding  
218 patterns by immunoblot, each recognising between 1 and 3 UP proteins. Three of the lambs  
219 raised antibodies only expressed by the infecting strain HPA5 with a mass of 70-72 kDa, and  
220 three of the lambs recognised a 50 kDa mass protein only expressed by HPA5. This 50 kDa  
221 band represents the major surface protein (multiple banded antigen; MBA) responsible for  
222 determining the serovar of the bacteria, and MBA reactivity for these sera was confirmed by

223 probing with a monoclonal antibody raised against the MBA (Figure 3B). Two of the lambs  
224 also raised antibodies against a 42 kDa protein that was expressed by both the inoculating  
225 serovar 3 strain HPA5 and serovar 6 strain HPA61, suggesting reactivity to a conserved UP  
226 protein.

227

228 ***Investigation of serum susceptibility of recovered plasma and amniotic fluid strains.***

229 UP strains recovered from the plasma of Group 2 lambs were examined to determine if they were  
230 less susceptible to serum killing than strains recovered from amniotic fluid from bacteraemic and  
231 non-bacteraemic lambs. Recovered isolates were separated into 3 groups: **i)** plasma-recovered  
232 isolates; **ii)** amniotic fluid recovered isolates from the same animals that had UP recovered from  
233 their plasma; and **iii)** amniotic fluid-recovered isolates from animals that did not have  
234 bacteraemia. Susceptibility to 50% (v/v) adult sheep sera and 50% (v/v) 95 d GA sera from  
235 Group 2 animals are shown in Figure 4. Isolates cultured directly from plasma were equally  
236 susceptible to sera as amniotic fluid-recovered isolates from matched or non-bacteraemic  
237 animals. All recovered isolates were equally resistant to non-immune sera from control 95 d GA  
238 Group 1 animals, except (paradoxically) for one of the plasma-derived isolates (animal 115).

239

240 ***Ureaplasma-cidal activity of sera from bacteraemic versus non-bacteraemic lambs.***

241 As no relative serum resistance was observed for isolates recovered from plasma compared to  
242 amniotic fluid, the capacity of the sera from bacteraemic and non-bacteraemic 95 d GA preterm  
243 lambs was compared for their individual capacity to kill the parental strain inoculated into the  
244 pregnant sheep. Endogenous UP in bacteraemic sera was removed by filtration through a 0.22µm  
245 filter and removal of endogenous UP was confirmed by titration of filtered sera in Ureaplasma  
246 selective medium. The serum killing from the 95 d GA UP-infected animals in Group 2 was  
247 higher for non-bacteraemic than bacteraemic with one exception (Figure 5; lamb 116), which  
248 was also the lamb with the lowest detectable UP bacteraemia levels (Figure 2). Further, it was

249 noted that the serum with the lowest UP killing activity was from the animal with the highest  
250 plasma titre of UP (lamb 115). These data suggested that killing capacity of the sera was directly  
251 linked to UP titres in the serum.

252

253 ***Complement activity of sera from bacteraemic versus non-bacteraemic lambs.***

254 Complement activity (measured by lysis of guinea pig erythrocytes) was examined for the sera  
255 from UP-infected and uninfected 95 d GA lambs from Group 1. Complement activity in serum  
256 from bacteraemic lambs was significantly lower at 50% and 25% dilutions than those found to  
257 have no UP in their plasma (non-bacteraemic) ( $p < 0.001$ ; Figure 6A). However, the complement  
258 function of 125 dGA lambs was significantly greater than both of these, but still about 4-times  
259 less active relative to the complement activity in adult sheep sera (Figure 6A). The individual  
260 values for each of these animals can be found in supplementary figure 1, which shows the lowest  
261 complement function was observed in the lamb with the highest UP titre (lamb 115;  $10^4$  culture  
262 units/mL in plasma); in contrast, the highest complement activity for the bacteraemic group was  
263 found in the lamb with the lowest UP plasma titre (lamb 116; 10 culture units/mL in plasma;  
264 Figure 2). Complement function for both bacteraemic and non-bacteraemic groups were  
265 representative of the range (30-95% lysis at 50% (v/v) sera dilution) observed from age matched  
266 (95 d GA) uninfected lambs from Group 1 (Figure 6B), indicating UP infection (or bacteraemia)  
267 did not influence the overall development of the complement system or consume complement  
268 through activation. Furthermore, a correlation between *Ureaplasma*-cidal activity and  
269 complement activity in 95 d GA sera, irrespective of experimental UP infection, was found  
270 (Pearson  $r = 0.93$ ,  $R^2 = 0.86$ ;  $p < 0.001$ ; Figure 7).

271

272

273 **DISCUSSION**

274 Neonates, particularly those born preterm (<37 weeks' gestation), are frequently  
275 immunologically compromised and are more susceptible to morbidity and mortality due to  
276 infections.<sup>19</sup> Previously, we developed a haemolysis assay to examine the complement function  
277 in sheep, as sheep erythrocytes are the common target for complement function in other species<sup>15</sup>  
278 and here we have extended use of our experimental intrauterine UP infection model to examine  
279 the role of complement insufficiency as a determining factor for development of in utero sepsis.  
280 Sepsis is a life-threatening response to infection leading to tissue and organ damage, often  
281 identified through the accompanying fever, tachycardia, tachypnea, and febrile morbidity. Due  
282 to the collection of samples in our experimental infection model at Caesarean-section delivery  
283 under euthanasia conditions, measurement of temperature, breathing and heart rate could not be  
284 obtained in a meaningful manner. Therefore, while we have examined bacteraemia as a surrogate  
285 marker of sepsis, it is important to note that sepsis (the body's response to infection) in patients  
286 can occur in absence of bacteraemia and still responds to antibiotic treatment.

287

288 The primary findings of this study are that *in vitro* and *in vivo* bactericidal capacity of fetal sheep  
289 sera diminished with increasing prematurity. This finding was reflected by the increased  
290 incidence of bacteraemia detected in lambs experimentally infected with UP delivered at 95 d  
291 GA (50%) relative to 125 d GA (10%) lambs. Within the 95 d GA cohort, the bactericidal serum  
292 activity was found directly correlated to the complement function in the serum ( $R^2=0.30$ ,  $p<0.05$ ).  
293 However, the relationship between UP killing and sera concentration was found to be a  
294 logarithmic function and analysis of  $\log_{10}$ -transformed UP killing relative to complement  
295 functional assay values (represented by sera lysis of guinea pig erythrocyte targets) had a much  
296 stronger correlation ( $R^2=0.86$ ;  $p<0.001$ ; Figure 7). With one exception (animal 116), fetuses with  
297 bacteraemia were found to have lowest complement function compared to non-bacteraemic

298 fetuses; although animal 116 also had the lowest UP plasma titre (Figure 2) and the highest  
299 complement function within this this group (Supplementary Figure 1A). The correlation between  
300 UP bactericidal activity and complement function was not influenced by experimental infection,  
301 suggesting that the natural variation in complement activity at 95 d GA determined whether UP  
302 infection in the amniotic fluid became systemic or not.

303

304 Interestingly, measurement of IgG levels in control 95 and 125 d GA sera (Groups 1 & 3; Figure  
305 3),  $1.6 \pm 0.2 \mu\text{g/ml}$  and  $2.1 \pm 0.5 \mu\text{g/ml}$  respectively, confirmed no transplacental maternal IgG  
306 transfer (maternal IgG levels were  $14,400 \pm 889 \mu\text{g/ml}$ ) which has been speculated to be due to  
307 placental structure<sup>16,17</sup> and lack of neonatal Fc expression in the placental tissues and blood  
308 vessels. Therefore, measured IgG levels in the fetal sera in experimentally UP-infected animals  
309 could only have originated from the fetal immune system. Only 1 animal from Group 2 (95 d  
310 GA) had elevated IgG (Figure 3A), but this sera failed to react with UP by immunoblot (Figure  
311 3B), and which was also the case for Group 5 (125 d GA, 10 d UP infection). However, variable  
312 immune response was observed for Group 4 (125 d GA, 42 d UP infection), but again the highest  
313 IgG concentration (137) did not correspond to strongest recognition of multiple UP proteins by  
314 immunoblot (Figure 3). On the basis of these observations, it is would appear that complement,  
315 rather than adaptive immune response plays a critical role in protecting or resolving fetal UP  
316 bacteraemia in pregnancy. Our inability to sample fetal blood prior to delivery prevented us from  
317 determining if the seropositive group represent those that were bacteraemic at earlier GA. The  
318 anti-UP antibodies can only be of fetal immune origin, as we have previously shown adult, but  
319 not fetal, sheep sera immunoglobulins cross-react with guinea pig erythrocytes<sup>15</sup> and this was not  
320 detected in any of the sera from the preterm lambs (data not shown).

321

322 The HPA5 strain is susceptible to human serum killing in the absence of specific anti-UP  
323 antibodies.<sup>14</sup> As with human serum studies with this strain, sheep serum bactericidal activity  
324 required the presence of calcium. However, we are unable to determine if the bactericidal activity  
325 in sheep is mediated by the classical or lectin pathways (both require calcium), as we lack the  
326 reagents to differentially block these pathways as was performed for human sera.<sup>14</sup> The increased  
327 presence of *Ureaplasma* spp. in the cord blood of human preterm neonates of increasing  
328 prematurity has also been identified in the previously published Alabama preterm study.<sup>4</sup>  
329 Furthermore, *Cassell et al.* found that *Ureaplasma* could be cultured from blood samples of 26%  
330 of 200 ventilated preterm neonates studied, showing that *Ureaplasma* bacteraemia is prevalent in  
331 this patient group.<sup>8</sup>

332 Sheep models have recently been developed to investigate hypoxic delivery complications and  
333 intrauterine inflammation induced by microbial infection or exposure to lipopolysaccharides.<sup>20-</sup>  
334 <sup>26</sup> None of these studies, however, has investigated the contribution of the complement system  
335 to disease pathogenesis or to the role of complement in controlling systemic infection, largely  
336 due to the current lack of reagents to measure and manipulate the sheep complement system. The  
337 present study thus represents a significant advance in our understanding of the pathophysiology  
338 of fetal bacteraemia in the setting of preterm birth.

339

340 In conclusion, experimental intrauterine UP infection establishes stable amniotic fluid levels that  
341 remain stable for weeks following the infection.<sup>27</sup> Highlighting the importance of  
342 gestation/complement function on fetal response to challenge, UP was detected in the cord blood  
343 of 50% of fetuses infected at 70 d GA and delivered at 95 d GA (Group 2), but only in 10% of  
344 lambs infected at 115 d GA and delivered at 125 d GA (Group 5). No bacteraemia was observed  
345 in lambs infected at 80 d GA and delivered at 125 d GA (Group 4), but this was the only group  
346 to show a UP-specific antibody response. Interestingly, a range of functional complement activity

347 was observed in uninfected 95 d GA preterm lambs, indicating that development of the  
348 complement system is variable in the normal population and is not influenced by intrauterine UP  
349 infection. In addition to advancing our understanding of fetal responses to UP infection, our  
350 results also suggest that a familial history of complement deficiency may increase the risk of fetal  
351 UP infection in pregnancy, concomitant with an increased risk of preterm birth and adverse  
352 neonatal outcomes.

353

354

355 **Acknowledgements:** The Authors wish to express their gratitude to Siemens Australia for the  
356 donation of Rapidpoint 500 reagents used in this study. MWK is supported by a National Health  
357 and Medical Research Council Project Grant (GNT1049148) and the Women and Infants  
358 Research Foundation. MSP is supported by a National Health and Medical Research Council  
359 Project Grant (GNT1010315). OBS is supported by the Microbiology and Infection  
360 Translational Research Group (MITReG) and the Children and Young People's Research  
361 Network (CYPRN) as part of the Welsh Government initiative to support research. Bilateral  
362 travel between Australian and UK laboratories was funded by an international exchange Royal  
363 Society Grant (IE130066). SA was supported by a PhD studentship funded by the Ministry of  
364 Higher Education, Iraq Embassy.

365

366

367

368

369

370

371

372



373

374

375

376

377

378

379

380

381

382

## 383 References:

384

385 1. Dunkelberger JR, Song WC. Complement and its role in innate and adaptive immune

386

responses. *Cell Res.* **2010**; 20(1):34-50. doi: 10.1038/cr.2009.139

387

2. McGreal EP, Hearne K, Spiller OB. Off to a slow start: under-development of the  
388 complement system in term newborns is more substantial following premature birth.

389

*Immunobiology.* **2012**; 217(2):176-86.

390

3. Källman J, Schollin J, Schalèn C, Erlandsson A, Kihlström E. Impaired phagocytosis  
391 and opsonisation towards group B streptococci in preterm neonates. *Arch Dis Child Fetal*

392

*Neonatal Ed.* **1998**; 78(1):F46-50.

393

4. Goldenberg RL, Andrews WW, Goepfert AR, Faye-Petersen O, Cliver SP, Carlo WA,  
394 Hauth JC. The Alabama Preterm Birth Study: umbilical cord blood *Ureaplasma*

395

*urealyticum* and *Mycoplasma hominis* cultures in very preterm newborn infants. *Am J*

396

*Obstet Gynecol.* **2008a**; 198(1):43.e1-5.

397

5. Viscardi RM. *Ureaplasma* species: role in neonatal morbidities and outcomes. *Arch*

398

*Dis Child Fetal Neonatal Ed.* **2014**; 99(1):F87-92. doi:10.1136/archdischild-2012-

399

303351.

400

6. Paralanov V, Lu J, Duffy LB, Crabb DM, Shrivastava S, Methé BA, Inman J, Yooseph

401

S, Xiao L, Cassell GH, Waites KB, Glass JI. Comparative genome analysis of 19

402

*Ureaplasma urealyticum* and *Ureaplasma parvum* strains. *BMC Microbiol.* **2012**;

403

12:88.

404

7. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm

405

birth. *Lancet* **2008b**; 371:75-84.

406

8. Cassell GH, Waites KB, Crouse DT, Rudd PT, Canupp KC, Stagno S, Cutter GR.

407

Association of *Ureaplasma urealyticum* infection of the lower respiratory tract with

- 408 chronic lung disease and death in very-low-birth-weight infants. *Lancet*. **1988**;  
409 2(8605):240-5.
- 410 9. Payne MS, Kemp MW, Kallapur SG, Kannan PS, Saito M, Miura Y, Newnham JP,  
411 Stock S, Ireland DJ, Kramer BW, Jobe AH. Intrauterine *Candida albicans* infection  
412 elicits severe inflammation in fetal sheep. *Pediatr Res*. **2014**; 75(6):716-22. doi:  
413 10.1038/pr.2014.35.
- 414 10. Wolfs TG, Kallapur SG, Knox CL, Thuijls G, Nitsos I, Polglase GR, Collins JJ,  
415 Kroon E, Spierings J, Shroyer NF, Newnham JP, Jobe AH, Kramer BW. Antenatal  
416 *Ureaplasma* infection impairs development of the fetal ovine gut in an IL-1-dependent  
417 manner. *Mucosal Immunol*. **2013**; 6(3):547-56. doi: 10.1038/mi.2012.97.
- 418 11. Moulton K, Ryan P, Christiansen D, Hopper R, Klauser C, Bennett W, Rodts-Palenik  
419 S, Willard S. Ex vivo bioluminescence imaging of late gestation ewes following  
420 intrauterine inoculation with lux-modified *Escherichia coli*. *Comp Immunol Microbiol*  
421 *Infect Dis*. **2009**; 32(5):429-38. doi: 10.1016/j.cimid.2008.02.001.
- 422 12. Kemp MW, Miura Y, Payne MS, Watts R, Megharaj S, Jobe AH, Kallapur SG, Saito  
423 M, Spiller OB, Keelan JA, Newnham JP. Repeated maternal intramuscular or  
424 intraamniotic erythromycin incompletely resolves intrauterine *Ureaplasma parvum*  
425 infection in a sheep model of pregnancy. *Am J Obstet Gynecol*. **2014**; 211(2):134.e1-9.
- 426 13. Aboklaish AF, Dordet-Frisoni E, Citti C, Toleman MA, Glass JI, Spiller OB.  
427 Random insertion and gene disruption via transposon mutagenesis of *Ureaplasma*  
428 *parvum* using a mini-transposon plasmid. *Int J Med Microbiol*. **2014**; 304(8):1218-25.
- 429 14. Beeton ML, Daha MR, El-Shanawany T, Jolles SR, Kotecha S, Spiller OB. Serum  
430 killing of *Ureaplasma parvum* shows serovar-determined susceptibility for normal  
431 individuals and common variable immuno-deficiency patients. *Immunobiology*. **2012**;  
432 217(2):187-94

- 433 15. Ahmed S, Kemp MW, Payne MS, Kallapur SG, Stock SJ, Marsh HC, Jobe AH,  
434 Newnham JP, Spiller OB. Comparison of complement activity in adult and preterm  
435 sheep serum. *Am J Reprod Immunol.* **2015**; 73(3):232-41
- 436 16. Cummings JN and Bellville TP. Studies on fetal physiology in the sheep.  
437 Transplacental passage of antibodies and techniques for repeated sampling of the fetal  
438 lamb in situ. **1963**; *Am J Obstet Gynecol.* 86:504-13.
- 439 17. Sammin, D., Markey, B., Bassett, H., Buxton, D. The ovine placenta and placentitis.  
440 **2009**; *Vet. Microbiol.*135:90–97.
- 441 18. Gokce E, Atakisi O, Kirmizigul AH, Unver A, Erdogan HM. Passive immunity in  
442 lambs: serum lactoferrin concentrations as a predictor of IgG concentration and its  
443 relation to health status from birth to 12 weeks of life. **2014**; 116:219-228
- 444 19. Strunk T, Inder T, Wang X, Burgner D, Mallard C, Levy O. Infection-induced  
445 inflammation and cerebral injury in preterm infants. *Lancet Infect Dis.* **2014**; 14(8):751-  
446 62.
- 447 20. Castillo-Melendez M., Baburamani AA, Cabalag C, Yawno T, Witjaksono A, Miller  
448 SL, Walker DW. Experimental modelling of the consequences of brief late gestation  
449 asphyxia on newborn lamb behaviour and brain structure. **2013**; *PLoS One* 8: e77377.
- 450 21. Wolfson MR, Hubert TL, Gregory TJ, Mazela J, Shaffer TH. Lucinactant attenuates  
451 pulmonary inflammatory response, preserves lung structure, and improves physiologic  
452 outcomes in a preterm lamb model of RDS. **2012**; *Pediatr Res* 72: 375-83.
- 453 22. Dean JM, van de Looij Y, Sizonenko SV, Lodygensky GA, Lazeyras F, Bolouri H,  
454 Kjellmer I, Huppi PS, Hagberg H, Mallard C. Delayed cortical impairment following  
455 lipopolysaccharide exposure in preterm fetal sheep. **2011**; *Ann Neurol*, 70, 846-56.

- 456 23 Kemp MW1, Saito M, Kallapur SG, Jobe AH, Keelan JA, Li S, Kramer B, Zhang L,  
457 Knox C, Yaegashi N, Newnham JP. Inflammation of the fetal ovine skin following in  
458 utero exposure to *Ureaplasma parvum*. **2011**; *Reprod Sci* 18: 1128-37.
- 459 24. Maneenil G, Payne MS, Senthamarai Kannan P, Kallapur SG, Kramer BW,  
460 Newnham JP, Miura Y, Jobe AH, Kemp MW. Fluconazole treatment of intrauterine  
461 *Candida albicans* infection in fetal sheep. **2015**; *Pediatr Res Basic Science Investigation*  
462 *77*: 740–748.
- 463 25. Zhang L, Saito M, Jobe A, Kallapur SG, Newnham JP, Cox T, Kramer B, Yang H,  
464 Kemp MW. Intra-amniotic administration of E coli lipopolysaccharides causes sustained  
465 inflammation of the fetal skin in sheep. **2012**; *Reprod Sci* 19:1181-9.
- 466 26. Hillman NH, Gisslen T, Polglase GR, Kallapur SG, Jobe AH. Ventilation-induced  
467 increases in EGFR ligand mRNA are not altered by intra-amniotic LPS or *Ureaplasma*  
468 in preterm lambs. **2014**; *PLOS One* 9: e96087.
- 469 27. Moss TJ, Nitsos I, Ikegami M, Jobe AH, Newnham JP. Experimental intrauterine  
470 *Ureaplasma* infection in sheep. *Am J Obstet Gynecol*. **2005**; 192(4):1179-86.  
471  
472

473 **FIGURE LEGENDS.**

474 **Figure 1. (A) Titration of *Ureaplasma*-cidal activity in non-immune sera.** UP killing by  
475 diluted sera from adult sheep (closed circle), 125 d GA preterm lambs (open square) and 95 d  
476 GA preterm lambs (grey triangle) following 1 h incubation at 37°C. Killing determined by  
477 relative decrease in UP titre compared to incubation with matched heat-inactivated sera controls.  
478 Each point represents average and standard deviation of sera from 4 separate animals (performed  
479 in duplicate). Results were repeated in 2 duplicate experiments.

480 **(B) UP killing kinetics of non-immune adult sheep and 95 d GA sera.** Sera diluted to 50%  
481 (v/v) in calcium and magnesium containing buffer (adult = closed circle, 95 d GA =closed  
482 square) were incubated with UP for various times before blocking further complement  
483 activation with addition of EDTA prior to titration of surviving UP. No serum killing of UP  
484 was observed if sera were diluted in alternative pathway buffer containing EGTA and  
485 magnesium (adult = open circle, 95 d GA = open square). Each point represents average and  
486 standard error of sera from 4 separate uninfected animals, killing calculated by decreased titre  
487 relative to UP titre following incubation with matched heat-inactivated sera. Data from one of  
488 three replicated experiments shown. Significant differences were found between all points by  
489 two factor ANOVA (dilution and age of serum source/addition of EGTA) and Bonferroni post-  
490 hoc analysis found significant reduction relative to adult serum killing for all data points after 5  
491 minutes incubation. Significant differences were found by two-factor ANOVA (dilution and age  
492 of donor) and Bonferroni post-hoc analysis found significant reduction relative to adult serum  
493 killing for all points but 125 d GA sera at 50% dilution.  $p < 0.01 = **$ ;  $p < 0.001 = ***$

494 **Figure 2. UP titres in cord plasma at delivery.** GA at delivery and total length of UP infection  
495 is indicated for each group. Each point represents the average as determined in triplicate. Data  
496 points for lambs 115 and 116 are separately identified for correlation purposes in other figures.  
497 Results were repeated in 2 duplicate experiments.

498 **Figure 3. (A) IgG concentration in 95 d and 125 d GA lambs.** ELISA determination of  
499 sheep IgG levels in sera from uninfected control lambs (Groups 1 and 3), compared to  
500 experimentally UP-infected lambs. Lambs 121 (Group 2) and 235 (Group 5) are identified as  
501 they have elevated IgG levels, but do not react with UP by immunoblot in (B). Results were  
502 repeated once.

503 **(B) Detection of anti-UP antibodies in fetal sera from infected lambs.** Purified whole UP  
504 cultures from the infecting serovar 3 strain (HPA5) and separate serovar 6 strain (HPA61) were  
505 separated by non-reducing SDS-PAGE and probed with fetal sera to detect immunoreactive  
506 bands by immunoblot analysis. Two infected lambs from Group 4 failed to raise specific anti-  
507 UP immune response (130 and 132) as well as all of the animals in Group 2 and 4 (only sera with  
508 elevated IgG from Groups 2 (121) and Group 4 (235) are shown). Four lambs in Group 4 raised  
509 an antibody response to proteins unique to the infecting strain and two of these lambs (136 and  
510 137) also raised cross-reacting antibodies that also recognised strain HPA61 which is a serovar  
511 6 isolate. The MBA isoforms for both strains are identified by mouse monoclonal antibody 6523.  
512 Representative results of 3 repeat experiments shown.

513 **Figure 4. Serum susceptibility of UP recovered from plasma or amniotic fluid.** Recovered  
514 strains were incubated for 30 min with 50% (v/v) adult sheep (A) or 50% (v/v) 95 d GA preterm  
515 lamb sera (B). Pooled sera from uninfected animals was used and each point was determined in  
516 duplicate. Representative data shown from 3 repeated experiments. Killing calculated as  
517 decreased titre relative to UP titre following incubation with matched heat-inactivated sera  
518 controls. One way ANOVA analysis found no difference between these groups.

519 **Figure 5. *Ureaplasma*-cidal activity from bacteraemic, non-bacteraemic, and uninfected 95**  
520 **d GA lambs.** Serum killing of HPA5 by 50% (v/v) sera from bacteraemic (plasma UP), non-  
521 bacteraemic (no plasma UP) and uninfected 95 d GA preterm lambs. Each point represents the  
522 average of 3 separate killing assays (each performed in duplicate). Killing calculated as decreased

523 titre relative to UP titre following incubation with matched heat-inactivated sera. Individual  
524 points for lambs 115 and 116 are identified.

525 **Figure 6. Functional complement activity as determined by guinea pig erythrocyte lysis**  
526 **assay after 30 min by diluted sera. A.** Complement activity for uninfected adult sheep (closed  
527 circles) and late preterm (125 dGA; closed squares) lamb sera are shown relative to complement  
528 function in sera from UP infected 95 dGA lambs with bacteraemia (+; open circles) and without  
529 bacteraemia (-; open squares). Two factor ANOVA (age of sera source and dilution) with  
530 Bonferroni post-hoc analysis found significantly increased complement function relative to  
531 infected 95 dGA lambs with bacteraemia for all points shown ( $p < 0.001 = ***$ ). Each point  
532 represents mean of triplicate values for  $N=4$  animals per group. **B.** For comparison a wide range  
533 of complement function was observed in control sera from uninfected lambs at 95 dGA,  
534 indicating UP bacteraemia doesn't reduce complement activity. Each point determined in  
535 triplicate, unique identifiers for each lamb are given. Results were repeated in 2 duplicate  
536 experiments.

537 **Figure 7. Correlation between complement activity and *Ureaplasma*-cidal activity.**  
538 Complement activity shown as haemolysis of 50% (v/v) sera at 30 min relative to fold-killing of  
539 50% (v/v) sera at 30 min at 37°C. Data for infected lambs with bacteraemia (plasma UP) or  
540 without bacteraemia (no plasma UP) and uninfected preterm lambs are separately identified.  
541 Each point determined in triplicate. Correlation for  $\log_{10}$  transformed killing data relative to lysis  
542 (Pearson  $r=0.93$ ;  $R^2=0.86$ ,  $p < 0.001$ ) shown for untransformed data.